$AEYE

Audioeye Q2 Earnings Call Highlights

AudioEye (NASDAQ:AEYE) reported Q2 net loss of $900,000, or $0.07/share, versus breakeven a year earlier, when a $1.4 million contingent consideration revaluation boosted results. Adjusted free cash flow was $2.6 million. Full-year adjusted EBITDA guidance rose to at least $12.7 million; revenue midpoint held at $43.5-$44.0 million. Q3 revenue forecast: $10.85-$11.05 million.

Original reporting
Published Aug 15, 2026, 5:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 15, 2026, 5:20 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Audioeye Q2 Earnings Call Highlights — source image
Decision brief

The 30-second read

$AEYEBullishMed
01

Why it matters

The key tradable items are the raised full-year adjusted EBITDA outlook, 2026 adjusted EPS guidance, and expectations for accelerating free cash flow in Q4 as litigation expense declines.

02

Market read

Guidance upgrades and cash-flow expectations can drive AEYE positioning, while Europe enforcement and recurring ARR mix are the main execution variables traders will monitor.

03

What to watch

Enterprise ARR is only 5% YoY and enterprise revenue is flat; the market may focus on whether recurring mix growth sustains margins beyond the midpoint assumptions.

Relevance 7/10Novelty 6/10Timing: post-earnings call, pre-next quarterly print

Background

AudioEye’s Q2 call focused on profitability improvement, recurring ARR mix, and Europe accessibility enforcement dynamics.

Company-level read

Ticker impact

$AEYEBullishMedium confidence
Context

AudioEye raised full-year adjusted EBITDA outlook to at least $12.7M and guided 2026 adjusted EPS to at least $0.98.

Expected impact

Moderate upside bias for AEYE on guidance-follow-through, with volatility tied to execution of recurring ARR growth and litigation expense normalization.

Evidence & confidence

The article discloses specific, time-bound forecast changes (EBITDA, EPS, free cash flow run-rate) plus Q3/Q4 expectations, which can drive trading decisions ahead of subsequent prints.

Market effects

Highlights ongoing regulatory-driven demand for digital accessibility tooling, with Europe enforcement cited as a potential demand inflection.

Europe is described as contributing more to ARR growth, with stepped-up enforcement in Sweden, Netherlands, Germany, and France.

Reinforces that WCAG/ADA compliance automation remains a cross-border compliance spend theme, not limited to the US.

Counterpoint

Raised EBITDA outlook may still depend on litigation expense trends and continued conversion from non-recurring to recurring revenue, which could disappoint if enforcement or partner expansion slows.

Key entities

  • AudioEye

    Provider of digital accessibility solutions, reporting Q2 results and updated full-year guidance.

  • WebAIM

    Study cited on the prevalence of WCAG failures across leading homepages.

  • European Accessibility Act

    Framework referenced as enforcement is still in early stages, with country-level actions cited.

Related articles

$AEYEHighAI 9/10

AudioEye Reports Record Second Quarter 2026 Results

AudioEye (Nasdaq: AEYE) reported Q2 2026 results for the quarter ended June 30, 2026. ARR rose to $42.3M from $41.2M sequentially and 11% YoY. Revenue increased 9% to $10.7M. Adjusted EBITDA was $3.0M. The company raised full-year adjusted EBITDA guidance and expects Q3 revenue $10.85M-$11.05M.

$AEYEMed

AUDIOEYE INC (AEYE): Results of Operations and Financial Condition

AUDIOEYE INC (AEYE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 aeye-20260813xex99d1.htm EX-99.1 ​ ​ Exhibit 99.1 ​ AudioEye Reports Record Second Quarter 2026 Results Forty-Second Consecutive Period of Record Revenue TUCSON, Ariz. — August 13, 2026 — AudioEye, Inc. (Nasdaq: AEYE) (“AudioEye” or the “Company”) , an industry-leading

$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

$AMATHighAI 9/10

Applied Materials Q3 Earnings Call Highlights

Applied Materials (AMAT) reported fiscal Q3 gross-margin expansion for a 13th straight quarter, citing AI-ecosystem product value, value-based pricing and operating leverage. For fiscal Q4, it projected revenue $10.25B plus or minus $500M and non-GAAP EPS $4.02 plus or minus $0.20. Semiconductor Systems revenue was $7.9B, and AGS revenue $1.8B.

$CVSMed

CVS Health Stock's Next Leg Sits In Aetna's Unfinished Margin Repair

CVS Health (CVS) shares were up 0.2% over three months as management raised full-year 2026 guidance for Health Care Benefits adjusted operating income by more than $1B, citing Aetna margin recovery. Enterprise adjusted EPS guidance is $7.90 to $8.10 and operating cash flow at least $11.5B. CVS flags 2027 headwinds at Caremark from 340B and membership declines.

$PLGOMed

Fidelis Insurance Q2 Earnings Call Highlights

Fidelis Insurance (FIHL) reported Q2 earnings call highlights. Management said Middle East war-related business since the conflict began had a loss ratio below 20%, and the broader war book generated over $1B premium at a sub-20% loss ratio. Quarterly combined ratio was 93.1%, with net favorable prior-year reserve development of $33M. Pelagos returned $73M via buybacks and maintained its dividend, reaffirming a mid-40% overall loss ratio.

Audioeye Q2 Earnings Call Highlights — alphai